Across TCGA pan-cancer cohorts, C12orf29 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C12orf29 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher C12orf29 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C12orf29 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
STAD and UCEC are the cancer types where C12orf29 Mutation most reproducibly stratifies survival.